Breakdown | ||||
Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
3.18B | 2.83B | 2.94B | 2.86B | 2.52B | Gross Profit |
1.06B | 948.20M | 954.60M | 957.30M | 813.30M | EBIT |
246.30M | 411.80M | 386.90M | 375.50M | 203.70M | EBITDA |
140.10M | 420.20M | 401.50M | 546.50M | 330.40M | Net Income Common Stockholders |
-211.00M | 569.70M | 208.90M | 249.90M | -53.40M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
199.30M | 242.90M | 234.10M | 446.10M | 302.20M | Total Assets |
5.24B | 5.55B | 3.87B | 4.01B | 3.99B | Total Debt |
2.03B | 2.10B | 1.31B | 1.32B | 1.67B | Net Debt |
1.83B | 1.86B | 1.08B | 872.40M | 1.37B | Total Liabilities |
3.78B | 3.88B | 2.76B | 2.78B | 2.91B | Stockholders Equity |
1.42B | 1.63B | 1.08B | 1.21B | 1.06B |
Cash Flow | Free Cash Flow | |||
137.10M | 137.70M | 140.80M | 488.40M | 318.90M | Operating Cash Flow |
191.30M | 207.00M | 191.10M | 528.40M | 354.80M | Investing Cash Flow |
26.80M | -729.90M | -143.40M | 126.00M | -1.30B | Financing Cash Flow |
-227.10M | 693.40M | -244.20M | -523.30M | 854.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $963.16M | 21.57 | 12.06% | 2.00% | 0.92% | 21.96% | |
68 Neutral | $1.90B | 31.27 | 9.29% | 0.79% | 2.67% | -18.41% | |
65 Neutral | $1.32B | 20.01 | 11.04% | 1.60% | 1.35% | -40.63% | |
64 Neutral | $4.25B | 11.69 | 5.23% | 249.83% | 4.04% | -9.46% | |
63 Neutral | $1.55B | ― | -15.50% | ― | 19.35% | 27.83% | |
50 Neutral | $1.95B | ― | -27.69% | ― | 23.46% | -1552.75% | |
48 Neutral | $1.39B | ― | -18.22% | 4.53% | 0.31% | -423.59% |
On April 29, 2025, Hillenbrand reported a 9% decrease in revenue for the fiscal second quarter ending March 31, 2025, primarily due to lower volume in the Advanced Process Solutions segment. The company completed the sale of its majority stake in the Milacron injection molding and extrusion business, using the proceeds to reduce debt and focus on more profitable sectors. Despite a challenging macroeconomic environment with increased tariffs and uncertainty, Hillenbrand remains optimistic about its long-term growth prospects and competitive positioning.
Spark’s Take on HI Stock
According to Spark, TipRanks’ AI Analyst, HI is a Neutral.
Hillenbrand’s overall stock score reflects a challenging environment with negative earnings and high leverage as primary concerns. Despite strategic restructuring and strong performance in certain segments, technical indicators are bearish, and valuation metrics are mixed, providing a moderate outlook.
To see Spark’s full report on HI stock, click here.
On March 31, 2025, Hillenbrand, Inc. completed the sale of its majority interest in the Milacron injection molding and extrusion business to Bain Capital for $287 million. This transaction, part of Hillenbrand’s strategic portfolio transformation, allows the company to focus on its core process and automation equipment for the food, pharmaceutical, and polymer markets. Hillenbrand retains a 49% stake in Milacron, while Bain Capital takes operational control, aiming to drive future growth and success for Milacron. The net proceeds of approximately $250 million after tax will be used to reduce Hillenbrand’s debt.